SYNPARK · Multimodal imaging in parkinsonisms: from the molecular synaptic pruning to the whole-brain connectomics
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2020-09-01 → 2023-08-31
- Финансиране от ЕС
- 232 498 €
- Участници
- 2
- Схема
- MSCA-IF
Линиите свързват координатора с партньорите.
Накратко на български
Маркери за плътността на синапсите и структурата на мозъка се анализират чрез PET и MRI сканиране при пациенти с паркинсонизъм. Този подход помага за по-точно разграничаване на болестта на Паркинсон от нейните атипични форми, което е важно за избора на подходяща терапия.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Multimodal imaging in parkinsonisms: from the molecular synaptic pruning to the whole-brain connectomics
Parkinsonism is the 2nd most prevalent neurodegenerative syndrome, global estimates in 2019 showed over 8.5 million people were diagnosed with Parkinson’s disease (PD) according to WHO, and this number is expected to grow as the world population ages. According to the European Parliament, its economic impact is estimated at 13.9 billion € per year. About 80% of the diagnosed patients have a classical form of idiopathic PD whereas the rest present some form of atypical parkinsonism (AP). Differential diagnosis between AP and PD poses significant challenges for clinicians as clinical manifestations can overlap and there are no gold standard biomarkers. As disease-modifying therapies are becoming available, an accurate diagnosis is essential because in AP neuronal degeneration is generally more rapid and widespread, symptomatic therapy less effective and therefore, there is a greater caregiver burden and a major economic impact. The overarching aim of the SYNPARK project was to investigate the potential discriminative power of multimodal imaging markers in improving parkinsonism diagnostic accuracy. To address such a complex question, we proposed the study of the most cutting-edge Positron Emission Tomography (PET) molecular imaging techniques in combination with Magnetic Resonance Imaging (MRI) modalities to provide a better insight into parkinsonism pathology. I explored the specific binding and kinetic properties of the newly developed [18F]SynVesT-1 tracer as an indirect measure of quantifying synaptic density loss in parkinsonian patients. I also worked with other PET and MRI modalities to investigate the protein deposition, neurochemical abnormalities, brain atrophy, and functional disruptions underlying the degenerative process of PD and study its clinical manifestations heterogeneity.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Neurodegenerative diseases affect more than 6 million people in Europe, and its prevalence is growing as population ages, hence it is a timeliness health challenge we are facing as a society. Parkinsonism is the 2nd most prevalent neurodegenerative form, being Parkinson’s disease (PD) the most frequent, whereas 20% of the patients are diagnosed with atypical parkinsonisms (AP). Despite presenting some clinical overlap, AP tends to be more therapy-resistant and have faster degeneration rates than PD. SYNPARK is an interdisciplinary project that will investigate the discriminative power of different imaging markers’ modalities in parkinsonisms. Improving diagnostic accuracy is crucial as disease-modifying therapies are becoming available for PD. For this challenge, I propose a multidisciplinary approach: from the in-vivo synaptic molecular brain assessment (using positron emission tomography, PET), the whole-brain connectomics organisation (using magnetic resonance imaging, MRI) to the clinics. I will conduct the outgoing phase in one of the world’s PET leading centres in Toronto to test the clinical validity of a new generation PET tracer in AP/PD. My host return institution (Barcelona) has pioneered the research on machine learning (ML) techniques that are revolutionising the medical sciences field to improve parkinsonisms’ differential diagnosis at the single-patient level by means of whole-brain MRI connectomics information. My current expertise and the proposed ambitious training objectives will position me at the forefront of this exciting new avenue in medical sciences and will enhance my professional independence for research leadership. Overall, the synergies established between these two leading centres are expected to have a tremendous impact on the understanding of AP/PD brain pathophysiology and its diagnostic accuracy, and ultimately enhancing a revolution in personalised medicine, a futuristic therapy that is increasingly becoming a reality.
Оригинален текст от CORDIS (на английски).
Участници
Връзки
Данни: CORDIS, © Европейски съюз